RxDoctor Payments DataLook up a doctor →

Mara Haseltine, MD

Dermatology · New Orleans, LANPI 1336317379

Payments from drug & device makers

$276,094in general payments, 2019–2025

Across 1,307 payments — averaging $211.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$82K
  • Dermavant Sciences, Inc.$71K
  • Galderma Laboratories, L.p.$58K
  • Organon$15K
  • Kyowa Kirin, Inc.$13K
  • Incyte Corporation$8K
  • plus $30K from 34 others

What the payments were for

  • Consulting fees$22,1198%
  • Speaking & faculty fees$198,80972%
  • Travel & lodging$26,67410%
  • Food & beverage$27,75810%
  • Education$7350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$276,094 in reported general payments places this provider in the 90th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$74,707
Medicare patients
189
Services billed
3,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib12$73,094
Bexarotene16$40,688
Tretinoin12$1,307
Clobetasol Propionate33$957
Hydroxychloroquine Sulfate18$741
Fluorouracil18$730
Doxycycline Hyclate29$706
Ketoconazole36$703
Dapsone13$663
Fluocinonide20$501
Minoxidil68$378
Triamcinolone Acetonide71$349
Finasteride43$319
ValacyclovirValacyclovir Hcl13$280
Mupirocin17$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$4,033$73,09412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 189 dermatology providers in Louisiana.

Other dermatology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →